Idorsia Ltd
Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland, the United States, Japan, Europe, China, and Canada. The company has a clinical development pipeline for various therapeutic areas, such as CNS, cardiovascular, immunological disorders, and orphan diseases. It offers QUVIVIQ (daridorexant) for the… Read more
Idorsia Ltd (IDRSF) - Total Liabilities
Latest total liabilities as of September 2025: $1.59 Billion USD
Based on the latest financial reports, Idorsia Ltd (IDRSF) has total liabilities worth $1.59 Billion USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Idorsia Ltd - Total Liabilities Trend (2016–2024)
This chart illustrates how Idorsia Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Idorsia Ltd Competitors by Total Liabilities
The table below lists competitors of Idorsia Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Quest Holdings S.A
AT:QUEST
|
Greece | €542.66 Million |
|
Shandong Weigao Orthopaedic Device Co. Ltd. A
SHG:688161
|
China | CN¥992.87 Million |
|
Yantai Ishikawa Sealing Technology Co.Ltd.
SHE:301020
|
China | CN¥239.17 Million |
|
Wuhu Sanlian Forging Co Ltd
SHE:001282
|
China | CN¥1.02 Billion |
|
Axiomtek Co Ltd
TWO:3088
|
Taiwan | NT$2.43 Billion |
|
KHVATEC Co.Ltd
KQ:060720
|
Korea | ₩172.59 Billion |
|
Acacia Research Corporation
NASDAQ:ACTG
|
USA | $192.03 Million |
|
DAEA TI Co. Ltd
KQ:045390
|
Korea | ₩145.62 Billion |
Liability Composition Analysis (2016–2024)
This chart breaks down Idorsia Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.40 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.40 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 3.50 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Idorsia Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Idorsia Ltd (2016–2024)
The table below shows the annual total liabilities of Idorsia Ltd from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $1.72 Billion | +16.98% |
| 2023-12-31 | $1.47 Billion | -6.16% |
| 2022-12-31 | $1.57 Billion | +13.52% |
| 2021-12-31 | $1.38 Billion | +62.23% |
| 2020-12-31 | $849.88 Million | +1.19% |
| 2019-12-31 | $839.85 Million | +12.11% |
| 2018-12-31 | $749.14 Million | +35.62% |
| 2017-12-31 | $552.37 Million | +35.67% |
| 2016-12-31 | $407.15 Million | -- |